The present invention relates to stable topical compo sitions which contain L-ascorbic acid and which pre-5 vent ultraviolet damage to skin. More particularly, it relates to topical compositions containing L-ascorbic acid (vitamin C) which are stabilized in aqueous solu tions by providing a concentration of L-ascorbic acid above about 1% (w/v) and maintaining the pH below about 3.5.
Considerable effort has been expended to find ways to prevent adverse changes in the skin brought about by ultraviolet (UV) exposure. Preventative approaches include physically blocking or absorbing the UV radia-15 tion before it can enter the skin. This technique is effec tive but is cumbersome because these prior art sun blockers or absorbers usually must be applied before every exposure and can be washed off with water.
Thus, for example, after every swim they must be reap-20 plied. Further, the long-term side effects of many of these prior art compositions are not known.
L-ascorbic acid has many known biological functions from enzymatic co-factor to "sparing' agent against vitamin E depletion. See, for example, Englard and Seifter, "The Biochemical Functions of Ascorbic Acid," Ann. Rev. Nutri. 6: 365-406, (1986) ; Kunert and Tappel, "The Effect of Vitamin C on in vivo Lipid Peroxidation in Guinea Pigs as Measured by Pentane and Ethane Production, Lipids 18: 271-74 (1983) . The latter function may partly account for its "anti-oxidant' status. Additionally, at higher concentrations, ascorbic acid is known to react with both the superoxide and hydroxyl radicals. Super oxide and the subsequently generated hydrogen perox ide and hydroxyl radical are oxygen-containing free radicals now known to be generated in vivo under a variety of normal and pathological conditions. Quite simply, these radicals have been implicated as causative agents for everything from sunburn to aging. These radicals destroy lipid membranes, break down DNA, inactivate enzymes and so forth. An immense amount of work has been done in the last two decades document ing the deleterious behavior of oxygen radicals. Several recent texts on the subject include: Review", Yale J. Biol. Med. 58:554-59 (1985) .
L-Ascorbic acid (or vitamin C), which has a long and illustrious history, is chemically defined as an a-ketolac tone with the following structure:
The number 2 and 3 carbons are double-bonded and contain an acid-ionizable hydrogen in water (pK = 4.2). Ascorbic acid is also a moderately strong reductant.
These properties, which lead to instability in the ascor bic acid structure, are well known and have been bur densome to pharmacologists when attempting to formu late active ascorbic acid solutions. Thus, at higher pH's, the ascorbic acid increasingly becomes the notoriously unstable ascorbate anion. This instability may be due to several causes not restricted to: 3 aqueous ascorbic acid solution by adding monothio glycerol and maintaining the pH between 4 and 7; U.S. Pat. No. 2,400, 171 which discloses stabilizing ascorbic acid by converting it to its calcium or zinc salt and preferably maintaining the pH at 7 to 7.3; U.S. Pat. No. 2,442,461 which discloses stabilizing calcium ascorbate by adding an aliphatic thiocarboxylic acid and maintain ing the pH between 5.2 and 5.6; U.S. Pat. No. 2,585,580 which discloses stabilizing ascorbic acid with thio-sug ars and maintaining the pH between 4.0 and 6.5; and U.S. Pat. No. 4,372,874 which discloses actually remov ing the water to below 0.5 wt.% by using a desiccant. In many cases, these techniques have been successful in obtaining stable solutions but have been reasonably expensive and have yielded a product with less desir able properties than ascorbic acid in its unmodified form.
We have now discovered a new, more economical, stable topical composition which consists essentially of at least about 1 wt.% L-ascorbic acid, preferably from about 3 to 20 wt.% L-ascorbic acid, and more prefera bly about 5 to 10 wt.% L-ascorbic acid in water and a carrier for topical application. Any composition con taining at least about 1 wt.% L-ascorbic acid is expected to have beneficial effects, with the concentration of L-ascorbic acid being primarily limited by its solubility in the water/carrier system. The ratio of water to car rier is at least 1:1, and more preferably from 2:1 to 10:1, and the pH of the composition is no more than about 3 to 3.5, preferably no more that about 2.5. Such a compo sition appears to allow ready penetration into the skin and retards the damage caused by ultraviolet light.
Carriers for topical application useful in practicing the invention include, but are not limited to, alkylene glycols, or alkylene glycols in combination with one or more derivatives of hydroxyalkylcellulose. In one en bodiment, the alkylene glycol is propylene glycol and the hydroxyalkylcellulose is hydroxypropylcellulose. When a combination of alkylene glycol and hydrox yalkylcellulose is used, a useful ratio of alkylene glycol to hydroxyalkylcellulose is from about 30:1 to 5:1 and a particularly useful ratio is 30. Without limitation, other carriers known to those skilled in the art which are compatible with water and are biologically acceptable are expected to provide equivalent compositions within the scope of this invention. For example, alcohols such as ethanol and propanol, glycols such as butylene or hexylene glycol, and polyols such as sorbitol may be employed. Alternatively, polyethylene or polypropyl ene glycols, mineral oil or glycerol can be used. Also contemplated by this invention are biologically accept able hydroxyalkylcelluloses.
As one skilled in the art would recognize, the ascor bic acid may be provided by the addition of any reduc ing analog of ascorbic acid, such as D-isoascorbic acid or perhaps by the addition of other small reducing com pounds such as, but not limited to, glutathione, L-cys teamine, etc. Such forms would be expected to provide an equivalent composition to that claimed and are within the scope of the invention.
The water used is preferably distilled and/or deion ized, but any water may be used which does not contain contaminants which would affect the stability of the ascorbic acid composition. The effects of water of vary ing purity on ascorbic acid stability is discussed in Meucci et al., "Ascorbic Acid Stability in Aqueous Solutions," Acta Vitaminol. Enzymol. 7(3-4): 147-54 (1985) , incorporated herein by reference. A metal chelator, such as diethylene triaminepentaa cetic acid (DTPA) or ethylenediamine-di(o-hydroxy phenylacetic acid) (EDDHA), can be added to the composition in minor amounts (.001% to 0.1% (w/v)) to provide additional stability to the ascorbic acid, par ticularly when used at the lower concentration.
The required pH of the composition ensures that greater than 82% of the ascorbic acid remains in the protonated, uncharged form. Although not wishing to be bound by theory, we believe that the protonated form of ascorbic acid used in our invention is important dermatologically for several reasons. First, this form removes the ionic repulsion of the two oxygen groups, thus stabilizing the molecule. Second, because the pro tonated form of ascorbic acid is uncharged, entry into the skin (which itself has a pH of about 3-5) should be facilitated. See H. Schaefer et al., Skin Permeability 739-40 (Springer-Verlag Co., Berlin, 1982) .
The following examples are for illustrative purposes only and are not intended to limit the scope of the claimed invention. The spectrophotometric analyses were made on a Shimadzu UV-260 dual beam spectro photometer under the following conditions: Samples of ascorbic acid were kept at room temperature (unless otherwise indicated), shielded from light with varying air headspace. At different times aliquots were taken from each sample and diluted into water in a quartz cuvette in the spectrophotometer "sample beam". The reference cell contained either vehicle diluted into water or water alone (no difference was detected). Spectra were then taken from 200 nm to 400 nm and the optical density at the absorption maximum (unless oth erwise indicated) was used to determine concentration. A concentrated solution of 0% L-ascorbic acid (w/v) is prepared by dissolving 10 g of L-ascorbic acid (avail able from Sigma) in 80 ml distilled, deionized water, and adding propylene glycol (1,2 propanediol purchased from Aldrich Chemical) to 100 ml. Optionally, 1 g of hydroxypropylcellulose (average molecular weight of 300,000) may be added. For maximum stability, the solution should be stored in a light-impermeable bottle at a temperature of about s22 C. with minimal head space and/or purged with nitrogen.
In Example I, four solutions of 10% L-ascorbic acid apparent that even at relatively high pH's, the L-ascor bic acid at a 5% concentration is quite stable.
EXAMPLE IV
Example IV illustrates that spectral changes occur in a 5% L-ascorbic acid solution in 80% H2O(v/v):20% propylene glycol(v/v):1% hydroxypropylcellulose (w/v) at relatively high pH even though the ascorbic acid is stable. From Example III, compositions at pH 2.4 and pH 4.2 were scanned either immediately after preparation or after 12 weeks storage as in Example III.
The spectra are illustrated in FIGS. 4 and 5. These results indicate that reactions are occurring at pH 4.2 which lead to spectral broadening of the major peak into the near UV, as manifested by an increased "yel lowing" of the solution.
EXAMPLE V Example V illustrates that by using distilled, deion ized H2O and high concentrations of ascorbic acid/as corbate used in the formulation (23%), chelators show only a slight tendency to to stabilize ascorbate. In com parison, when a 1% ascorbate solution in a propylene glycol/ethanol/H2O vehicle was made with or without oil mM DTPA, a slight protective effect of DTPA on the stability of ascorbate was found. With a 5% ascor bate solution in propylene glycol/H2O however, DTPA no longer showed any protective effect when analyzed spectrophotometrically. The data are pres ented in Table I . The chelator effect is expected to increase in compositions which are formulated in less pure water than those used for Example V, or those in which any of the components are contaminated with metal ions.
EXAMPLE VI
Example VI illustrates the greater stability of L ascorbic acid compared to that of Na-ascorbate in the cosmetic preparation of 80% H2O:20% propylene gly col: 1% hydroxypropylcellulose at a concentration of 1% (w/v) and 10% (w/v). At 1%, L-ascorbic acid is slightly more stable than the sodium salt, ascorbate. At 10% concentration, both L-ascorbic acid and Na-ascor bate show pronounced stability based on the spectro photometric analyses, but the Na-ascorbate shows con siderable yellow discoloration at both concentrations after 2 weeks whereas L-ascorbic acid shows only slight changes even at 7 weeks. The results are tabulated in Table II . other difference relates to the overall stain intensity, an indication of an edematous response in skin. Quite typi cally, the sections from non-treated, exposed skin stain less than sections taken from ascorbic acid-treated skin, indicating a decreased edematous response in protected skin.
EXAMPLE VIII
Example VIII illustrates the reservoir effect of L ascorbic acid protection against UV damage to the skin. Animals treated as in Example VII receive the final pretreatment 4 hours before UV exposure. In addition all treated sites are washed with luke-warm water in mediately prior to irradiation eliminating any residual solution acting as a sunblock. This establishes that pro tection is due to L-ascorbic acid which has been taken up by the skin. This is in contrast to typical, commer cially available, sunscreens which have to be applied immediately prior to exposure for optimal performance.
EXAMPLE IX
Example IX illustrates the potential of topical appli cations of L-ascorbic acid to moderate severe ultravio let-induced skin damage. In Example IX, the test animal was pretreated with a 5% formulation of L-ascorbic acid (in either an aqueous formulation or "hydroalco holic" vehicle) five times in six days prior to irradiation. On the sixth day, the treated and control areas were irradiated for 60 minutes with a bank of two Westing house FS-40 bulbs. This dose is equivalent to 30 times the minimal erythemal dose. The photograph was taken 11 days after irradiation showing the improvement in appearance of the L-ascorbic acid treated sites as com pound to the control sites . The results are illustrated photographically in FIG. 7. EXAMPLE X Example X establishes that topical application of the aqueous L-ascorbic acid formulation has beneficial, "wound healing", effects even when applied after UV irradiation, as illustrated photographically in FIG. 8. In Example X, the test animal was pretreated and irradi ated as in Example IX. One area on this animal (the bottom row in the illustration of FIG. 8) received no pretreatment. After irradiation, the sites received either no post-treatment, or post-treatment on one, two, three, four, five, or seven days with 5% L-ascorbic acid, or post-treatment with the vehicle only for seven days. With 3 to 4 days post-treatment with the L-ascorbic acid solution (I-J in FIG. 8) , the appearance of skin improved as compared to those areas which were un treated or treated with vehicle only. 5,140,043 7 TOXCITY STUDIES Although no formal toxicity studies have been con ducted, a 10% solution (w/v) has been applied to the face of a human one time per day, five times per week 5 for thirty weeks without any adverse reaction. Addi tionally, in preliminary studies carried out by Dr. Lor raine Kligman at the University of Pennsylvania, hair less mice were treated 5 times per week with either a 5% or 0% solution of L-ascorbic acid at either pH 2.1 or 3, or with the pH controls for 4 weeks. No evidence (clinical or histological) was found for these topical applications being either toxic or irritating. H2O:20% propylene glycol:1% hydroxypropylcel lulose. The samples were kept in the dark at room tem perature in capped microfuge tubes (with an approxi mately 10% air headspace). Aliquots were taken at the indicated times and measured for residual ascorbic acid /ascorbate spectrophotometrically.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 shows the stability of various concentrations of L-ascorbic acid in aqueous cosmetic vehicle. Differ ent concentrations of L-ascorbic acid were made in a vehicle composed of 80% H2O, 20% propylene glycol and 1% hydroxypropylcellulose and stored shielded from light, at room temperature (with an approximately 10% air headspace). One day, 3 weeks and 7 weeks later, aliquots were diluted into a quartz cuvette and the resulting spectrum was scanned from 200 to 400 nm. The optical density of the 260-265 nm peak was re corded for lower concentrations while the optical den sity at 280 nm was recorded for changes in the higher concentrations of L-ascorbic acid. FIG . 6 shows the photomicrographs of ultraviolet irradiated porcine skin treated with an aqueous L ascrobic formulation or vehicle control. Sites on ani mals back were pretreated with the ascrobic acid or vehicle control eight times in the six days prior to irradi ation, the last predetermined being 4 hours before irra diation. Irradiation was for 10 minutes using a bank of two Westinghous FS-40 sunlamps. Four millimeter punch biopsys were taken 24 hours later, routinely fixed and stained with (Hematoxylian and Eosin). Arrows point to sunburn cells. FIG. 7 shows the effect of 5% L-ascorbic acid in aqueous formulation and of 5% L-ascorbic acid in "hy droalcoholic' vehicle on acute sunburn in the domestic pig. The two ascrobic acid solutions (or their vehicle alone) were applied liberally 5 times in 6 days. On the seventh day, the animal was exposed for 60 minutes to ultraviolet irradiation (two FS-40 sunlamps at a distance of 4-inches). Photograph was taken 11 days post-irradia tion. VC-I=5% L-ascorbic acid in aqueous formula 5,140,043 L-AA, 7 days post-exposure. Vehicle sites were treated with the VC-I vehicle for the seven days post-exposure.
We claim: 1. A topical composition consisting essentially of from at least about 1% ascorbic acid (w/v) in water and 5 a carrier suitable for topical application wherein the ratio of water to carrier is at least 1:1 and wherein the composition has a pH of no more than about 3.5.
2. The composition of claim 1 wherein the carrier comprises an alkylene glycol.
3. The composition of claim 2 wherein the alkylene glycol is propylene glycol.
4. The composition of claim 1 wherein the carrier is a combination of an alkylene glycol and hydroxyalkylcel lulose.
5. The composition of claim 4 wherein the alkylene glycol is propylene glycol.
6. The composition of claim 1 wherein the ratio of water to carrier is from about 2:1 to about 10:1.
7. The composition of claim 2 wherein the ratio of 20 water to carrier is from about 2:1 to about 10:1.
8. The composition of claim 3 wherein the ratio of water to carrier is from about 2:1 to about 10:1. 9. A topical composition consisting essentially of between 3 and 20% ascorbic acid (w/v) and 80% to 25 97% water and a carrier suitable for topical application wherein the ratio of water to carrier is at lest about 1:1 and wherein the composition has a pH of no more than about 3.5.
10. The composition of claim 9 wherein the carrier is 30 a combination of an alkylene glycol and hydroxyalkyl cellulose.
11. The composition of claim 10 wherein the ratio of alkylene glycol to hydroxyalkylcellulose is from about 30:1 to S:1.
12. The composition of claim 11 wherien the alkylene glycol is propylene glycol and the hydroxylalkycel lulose is hydroxypropylcellulose.
13. The composition of claim 1 or 9 wherein the composition is a dermatogical composition and the car rier is a dermatological carrier.
14. The composition of claim 1 or 9 wherein the pH is no more than about 2.5.
15. The composition of claim 1 wherein the water is selected from the group consisting of distilled, deion ized and distilled deionized water.
16. The composition of claim 15 wherien the pH is no more than about 2.5. 17. A topical composition consisting essentially of about 5 to 10% ascorbic acid (w/v) and about 90 to 50 95% water and a carrier suitable for topical application wherein the ratio of water to carrier is at least about 1:1 and wherein the composition has a pH of no more than about 3.5. O water to carrier is at least 1:1 and wherein the composi tion has a pH of no more than about 3.5.
The composition of claim
23. The composition of claim 22 wherein the cos metic carrier comprises an alkylene glycol.
24. The composition of claim 23 wherein the pH is no more than about 2.5. A .
25. The composition of claim 22 wherein the water is selected from the group consisting of distilled, deion ized and distilled deionized water.
26. The composition of claim 25 wherein the Ph is no more than about 2.5.
27. The composition of claim 22 wherein the compo sition is a dermatoligical composition and the carrier is a dermatological carrier.
28. The composition of claim 23 wherein the ratio of water to carrier is from about 2:1 to about 10:1.
29.
A topical composition containing between 320% ascorbic acid (w/v) and 80% to 97% water and a car rier suitable for topical application wherein the ratio of water to carrier is at least about i:1 and wherein the composition has a pH of no more than about 3.5.
30. The composition of claim 29 wherein the carrier is a combination of an alkylene glycol and hydroxyalkyl cellulose.
31.
A topical composition containing about 5 to 10% ascorbic acid (w/v) and about 90 to 95% water and a carrier suitable for topical application wherein the ratio of water to carrier is at least about 1:1 and wherein the composition has a pH of no more than about 3.5. 32. A method of retarding damage to skin by ultravio let light which comprises applying a topical composi tion on the skin consisting essentially of at least about 1% ascorbic acid (w/v) in water and a carrier suitable for topical application wherein the ratio of water to carrier is at least about 1: 1 and wherein composition has a pH of mo more than about 3.5.
33. The method of claim 32 wherein the topical com position consists essentially of between about 3 and 20% ascorbic acid (w/v) and 80 to 97% water and carrier (v/v).
34. The method of claim 33 wherein the carrier con prises an alkylene glycol and hydroxyalkylcellulose. 35 . The method of claim 34 wherein the alkylene glycol is propylene glycol and the hydroxyalkylcel lulose is hydroxypropylcellulose. 36 . The method of claim 34 wherein the ratio of water to carrier is from about 2: to about 10:1.
37. The method of claim 35 wherein the ratio of water to carrier is from about 2:1 to about 10:1. 38. A method of preventing damage to skin by ultra violet light comprising the step of applying a topical composition to the skin consisting essentially of from at least about 1% ascorbic acid (w/v) in water and a car rier suitable for topical application wherein the ratio of water to carrier is at least 1:1 and wherein the composi tion has a pH of no more than about 3.5.
39. The method of claim 38 wherein the topically applied composition consists essentially of between 3 and 20% ascorbic acid (w/v) and 80% to 97% water and a carrier suitable for topical application wherein the ratio of water to carrier is at least about 1:1 and wherein the composition has a pH of no more than about 3.5. 40. A method of treating damage to skin by ultravio let light comprising the step of applying a topical com position to the skin consisting essentially of from at least about 1% ascorbic acid (w/v) in water and a carrier suitable for topical application wherein the ratio of
